Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy

Nature

Volumn 455, Issue 7217, 2008, Pages 1205-1209

  Wang, Zhong ^a   Smith, Kevin S ^a   Murphy, Mark ^a   Piloto, Obdulio ^a   Somervaille, Tim C P ^a   Cleary, Michael L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MIXED LINEAGE LEUKEMIA PROTEIN; PROTEIN SERINE THREONINE KINASE;

BLOOD SYSTEM DISORDER; DISEASE TREATMENT; ENZYME ACTIVITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; GENE MUTATION; GENE REPRESSION; LYMPHATIC LEUKEMIA; MOUSE; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; G1 PHASE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; LEUKEMIA, LYMPHOID; MICE; MICE, INBRED C57BL; MICE, SCID; MYELOID PROGENITOR CELLS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELLS, B-LYMPHOID;

MURINAE;

EID: 55249120170     PISSN: 00280836     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/nature07284     Document Type: Article

References (43)

1. Doble, B. W. & Woodgett, J. R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186 (2003).
2. Kim, L. & Kimmel, A. R. GSK3 at the edge: regulation of developmental specification and cell polarization. Curr. Drug Targets 7, 1411-1419 (2006).
3. Cohen, P. & Frame, S. The renaissance of GSK3. Nature Rev. Mol. Cell Biol. 2, 769-776 (2001).
4. Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W. & Roach, P. J. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262, 14042-14048 (1987).
5. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M. & Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
6. Kaidanovich, O. & Eldar-Finkelman, H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin. Ther. Targets 6, 555-561 (2002).
7. Hoeflich, K. P. et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 406, 86-90 (2000).
8. Martin, M., Rehani, K., Jope, R. S. & Michalek, S. M. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nature Immunol. 6, 777-784 (2005).
9. De Ferrari, G. V. & Inestrosa, N. C. Wnt signaling function in Alzheimer's disease. Brain Res. Rev. 33, 1-12 (2000).
10. Miller, J. R. & Moon, R. T. Signal transduction through β-catenin and specification of cell fate during embryogenesis. Genes Dev. 10, 2527-2539 (1996).
11. Jia, J. et al. Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature 416, 548-552 (2002).
12. Miller, J. R. The Wnts. Genome Biol 3, 3001 (2002).
13. Yost, C. et al. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10, 1443-1454 (1996).
14. van Noort, M., Meeldijk, J., van der Zee, R., Destree, O.& Clevers, H. Wnt signaling controls the phosphorylation status of β-catenin. J. Biol. Chem. 277, 17901-17905 (2002).
15. Sears, R. et al. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514 (2000).
16. Nikolakaki, E., Coffer, P. J., Hemelsoet, R., Woodgett, J. R. & Defize, L. H. Glycogen synthase kinase 3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells. Oncogene 8, 833-840 (1993).
17. Trowbridge, J. J., Xenocostas, A., Moon, R. T. & Bhatia, M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nature Med. 12, 89-98 (2006).
18. Sato, N., Meijer, L., Skaltsounis, L., Greengard, P. & Brivanlou, A. H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nature Med. 10, 55-63 (2004).
19. Ayton, P. M. & Cleary, M. L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20, 5695-5707 (2001).
20. Hess, J. L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10, 500-507 (2004).
21. Lavau, C., Szilvassy, S. J., Slany, R. & Cleary, M. L. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRXENL. EMBO J. 16, 4226-4237 (1997).
22. Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257-268 (2006).
23. Watase, K. et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 4, e182 (2007).
24. Polakis, P. The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev. 9, 15-21 (1999).
25. Testa, J. R. & Tsichlis, P. N. AKT signaling in normal and malignant cells. Oncogene 24, 7391-7393 (2005).
26. kip1: a target for tumor therapies? Cell Div. 2, 13 (2007).
27. Milne, T. A. et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA 102, 749-754 (2005).
28. Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207-218 (2005).
29. Hughes, C. M. et al. Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol. Cell 13, 587-597 (2004).
30. kip1) expression. Proc. Natl Acad. Sci. USA 102, 14028-14033 (2005).
31. kip1 protein. Cell Cycle 6, 580-588 (2007).
32. G.-Amlak, M. et al. Regulation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway. Biochem. Biophys. Res. Commun. 297, 760-764 (2002).
33. Dimartino, J. F. & Cleary, M. L. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br. J. Haematol. 106, 614-626 (1999).
34. Chen, C. S. et al. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood 81, 2386-2393 (1993).
35. Gould, T. D. & Manji, H. K. The Wnt signaling pathway in bipolar disorder. Neuroscientist 8, 497-511 (2002).
36. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006).
37. Smith, K. S., Rhee, J. W. & Cleary, M. L. Transformation of bone marrow B-cell progenitors by E2A-HlF requires coexpression of BCL-2. Mol. Cell. Biol. 22, 7678-7687 (2002).
38. So, C. W. et al. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3, 161-171 (2003).
39. Smith, K. S., Jacobs, Y., Chang, C. P.&Cleary, M. L. Chimeric oncoprotein E2a-Pbx1 induces apoptosis of hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2. Oncogene 14, 2917-2926 (1997).
40. Kasper, L. H. et al. CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity. Mol. Cell. Biol. 19, 764-776 (1999).
41. Kohn, A. D. et al. Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J. Biol. Chem. 273, 11937-11943 (1998).
42. So, C. W. & Cleary, M. L. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol. Cell. Biol. 22, 6542-6552 (2002).
43. Ventura, A. et al. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl Acad. Sci. USA 101, 10380-10385 (2004).